Powered by

Thyas Obtains Exclusive Rights to Manufacture Induced Pluripotent Stem Cells-Derived Killer T Cells for Autologous Immunotherapy

Jan 17, 2019 - GlobeNewswire

KYOTO, Japan, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Thyas Co. Ltd. (Thyas) signed a licensing agreement with iPS Academia Japan, Inc. (iPS-AJ), a technology licensing organization of induced pluripotent stem (iPS) cell related-patents from Kyoto University. Under the agreement, Thyas obtains exclusive rights on patents related to production and use of iPS cell-derived T cells, and non-exclusive rights on the patents related to iPS cell generation, for development and commercialization of autologou...